News

While the first forms the basis of a new program focused on identifying a respiratory disease treatment, the other is related to a program in inflammatory pain. As

According to the 10-year agreement, Cipla will be responsible for the development, manufacturing and supply of the drug product. Akorn will be responsible for the regulatory submission with

The main items in the report are: Highlights Operating profit improved by NOK16.7 million to NOK-5.7 million (NOK-22.5 million) Liquid funds amounted to NOK161.9 million at the end

Retigabine is a first-in-class neuronal potassium channel opener demonstrated to be effective in a recently published Phase IIb epilepsy study. The RESTORE1 and RESTORE2 (retigabine efficacy and safety

The study is designed to evaluate efficacy of topically applied PH-10 in a total of 25 subjects. In the study, PH-10 will be topically applied twice weekly for

In this trial, ChronVac-C will be administered using Inovio’s MedPulser DNA delivery system, in 12 subjects already infected with hepatitis C virus. The trial is being conducted in

Under the terms of the agreement, Elan will receive from Zogenix an undisclosed upfront payment and future payments upon the achievement of clinical and regulatory milestones for the

With this agreement, Cardinal Health will have exclusive US rights to distribute Lymphoseek for an initial term of five years following FDA clearance to market the product. David

INOmax (nitric oxide) is indicated for the treatment of near- and full-term newborns who suffer from hypoxic respiratory failure (HRF), a potentially life-threatening condition that keeps babies’ lungs